<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32326346</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>21</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>A&#x3b2;1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2911</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21082911</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, but its definitive diagnosis delays around 12 months. Although the research is highly active in the biomarker field, the absence of specific biomarkers for diagnosis contributes to this long delay. Another strategy of biomarker identification based on less specific but sensitive molecules may be of interest in clinical practice. For example, markers related to other neurodegenerative diseases such as Alzheimer's disease (AD) could be fully explored. Here, we compared baseline levels of amyloid&#x3b2;1-42 (A&#x3b2;1-42), total Tau, and phosphorylated-Tau (phospho-Tau) protein in the cerebrospinal fluid (CSF) of ALS patients to controls and correlated it with clinical parameters of ALS progression collected over 12 months. We observed increased levels of A&#x3b2;1-42 (controls: 992.9 &#xb1; 358.3 ng/L; ALS: 1277.0 &#xb1; 296.6 ng/L; <i>p</i> &lt; 0.0001) and increased A&#x3b2;1-42/phospho-Tau ratio and Innotest Amyloid Tau Index (IATI) (both <i>p</i> &lt; 0.0001). IATI and the phospho-Tau/total Tau ratio correlated positively with ALSFRS-R and weight at baseline. Multivariate analysis revealed that baseline ALSFRS-R was associated with A&#x3b2;1-42 and phospho-Tau/total Tau ratio (<i>p</i> = 0.0109 and <i>p</i> = 0.0013, respectively). Total Tau and phospho-Tau levels correlated negatively with ALSFRS-R variation at months 6 and 9, respectively (<i>p</i> = 0.02 and <i>p</i> = 0.04, respectively). Phospho-Tau/total Tau ratio correlated positively with ALSFRS-R variation at month 9 (<i>p</i> = 0.04). CSF levels of A&#x3b2;1-42 could be used as a complementary tool to ALS diagnosis, and total Tau and phospho-Tau levels may help establishing the prognosis of ALS. Further studies merit exploring the pathophysiological mechanisms associated with these markers. Despite their lack of specificity, phospho-Tau/total Tau and A&#x3b2;1-42 should be combined to other biological and clinical markers in order to improve ALS management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lanznaster</LastName><ForeName>D&#xe9;bora</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5911-3120</Identifier><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hergesheimer</LastName><ForeName>Rudolf C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakkouche</LastName><ForeName>Salah Eddine</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Centre Constitutif SLA, CHRU Bretonneau, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltran</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4718-0902</Identifier><AffiliationInfo><Affiliation>Centre Constitutif SLA, CHRU Bretonneau, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andres</LastName><ForeName>Christian R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dufour-Rainfray</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Tours, Service de MNIV, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre Constitutif SLA, CHRU Bretonneau, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Tours, Service de MNIV, 37000 Tours, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">A&#x3b2;1-42</Keyword><Keyword MajorTopicYN="N">CSF</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">total Tau</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32326346</ArticleId><ArticleId IdType="pmc">PMC7216266</ArticleId><ArticleId IdType="doi">10.3390/ijms21082911</ArticleId><ArticleId IdType="pii">ijms21082911</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D., de Assis D.R., Corcia P., Pradat P.F., Blasco H. Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS. Front. Neurol. 2018;9:1126. doi: 10.3389/fneur.2018.01126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01126</ArticleId><ArticleId IdType="pmc">PMC6305341</ArticleId><ArticleId IdType="pubmed">30619076</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K., Van Damme P. Diagnostic and Prognostic Performance of Neurofilaments in ALS. Front. Neurol. 2018;9:1167. doi: 10.3389/fneur.2018.01167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer&#x2019;s disease. Trends Neurosci. 1993;16:460&#x2013;465. doi: 10.1016/0166-2236(93)90078-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-2236(93)90078-Z</ArticleId><ArticleId IdType="pubmed">7507619</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289:2094&#x2013;2103. doi: 10.1001/jama.289.16.2094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.289.16.2094</ArticleId><ArticleId IdType="pubmed">12709467</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T., Stieler J., Holzer M. Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer&#x2019;s disease pathology. J. Neural. Transm. (Vienna) 2015;122:531&#x2013;539. doi: 10.1007/s00702-014-1342-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-014-1342-8</ArticleId><ArticleId IdType="pubmed">25480630</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakota L., Brandt R. Tau Biology and Tau-Directed Therapies for Alzheimer&#x2019;s Disease. Drugs. 2016;76:301&#x2013;313. doi: 10.1007/s40265-015-0529-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-015-0529-0</ArticleId><ArticleId IdType="pmc">PMC4757605</ArticleId><ArticleId IdType="pubmed">26729186</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Jimenez F.J., Hernanz A., Medina-Acebron S., de Bustos F., Zurdo J.M., Alonso H., Puertas I., Barcenilla B., Sayed Y., Cabrera-Valdivia F. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 2005;111:114&#x2013;117. doi: 10.1111/j.1600-0404.2005.00370.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2005.00370.x</ArticleId><ArticleId IdType="pubmed">15644071</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Petzold A., Sussmuth S.D., Ludolph A.C., Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66:852&#x2013;856. doi: 10.1212/01.wnl.0000203120.85850.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000203120.85850.54</ArticleId><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladino P., Valentino F., Piccoli T., Piccoli F., La Bella V. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur. J. Neurol. 2009;16:257&#x2013;261. doi: 10.1111/j.1468-1331.2008.02405.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2008.02405.x</ArticleId><ArticleId IdType="pubmed">19138331</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M., Elman L., McCluskey L., McMillan C.T., Boller A., Powers J., Rascovsky K., Hu W., Shaw L., Irwin D.J., et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:442&#x2013;448. doi: 10.1001/jamaneurol.2013.6064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6064</ArticleId><ArticleId IdType="pmc">PMC3989393</ArticleId><ArticleId IdType="pubmed">24492862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C., Deuschle C., Rattay T.W., Maetzler W., Synofzik M. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. Neurobiol. Aging. 2015;36:1072&#x2013;1074. doi: 10.1016/j.neurobiolaging.2014.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.10.019</ArticleId><ArticleId IdType="pubmed">25453560</ArticleId></ArticleIdList></Reference><Reference><Citation>Sussmuth S.D., Tumani H., Ecker D., Ludolph A.C. Amyotrophic lateral sclerosis: Disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci. Lett. 2003;353:57&#x2013;60. doi: 10.1016/j.neulet.2003.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2003.09.018</ArticleId><ArticleId IdType="pubmed">14642437</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine T.D., Bowser R., Hank N., Saperstein D. A pilot trial of memantine and riluzole in ALS: Correlation to CSF biomarkers. Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group Motor Neuron Dis. 2010;11:514&#x2013;519. doi: 10.3109/17482968.2010.513052.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.513052</ArticleId><ArticleId IdType="pubmed">20839903</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarafino A., D&#x2019;Errico E., Introna A., Fraddosio A., Distaso E., Tempesta I., Morea A., Mastronardi A., Leante R., Ruggieri M., et al. Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. J. Neurol. 2018;265:2353&#x2013;2362. doi: 10.1007/s00415-018-9008-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-9008-3</ArticleId><ArticleId IdType="pubmed">30116940</ArticleId></ArticleIdList></Reference><Reference><Citation>Calingasan N.Y., Chen J., Kiaei M., Beal M.F. Beta-amyloid 42 accumulation in the lumbar spinal cord motor neurons of amyotrophic lateral sclerosis patients. Neurobiol. Dis. 2005;19:340&#x2013;347. doi: 10.1016/j.nbd.2005.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.01.012</ArticleId><ArticleId IdType="pubmed">15837590</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Hendrich C., Sperfeld A.D., Jesse S., Lehnert S., Pabst A., von Arnim C.A., Mottaghy F.M., Uttner I., Tumani H., et al. Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. J. Neural Transm. (Vienna) 2009;116:1169&#x2013;1178. doi: 10.1007/s00702-009-0271-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-009-0271-4</ArticleId><ArticleId IdType="pubmed">19649690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamalainen A., Herukka S.K., Hartikainen P., Helisalmi S., Moilanen V., Knuuttila A., Jansson L., Tienari P.J., Remes A.M. Cerebrospinal fluid biomarkers for Alzheimer&#x2019;s disease in patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis with the C9ORF72 repeat expansion. Dement. Geriatr. Cogn. Disord. 2015;39:287&#x2013;293. doi: 10.1159/000371704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000371704</ArticleId><ArticleId IdType="pubmed">25791939</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkle A., Moreno-Villanueva M., Bernhard J., Blasco M., Zondag G., Hoeijmakers J.H., Toussaint O., Grubeck-Loebenstein B., Mocchegiani E., Collino S., et al. MARK-AGE biomarkers of ageing. Mech. Ageing Dev. 2015;151:2&#x2013;12. doi: 10.1016/j.mad.2015.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2015.03.006</ArticleId><ArticleId IdType="pubmed">25818235</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S., Mometto N., Bartoletti-Stella A., Polischi B., Oppi F., Poda R., Stanzani-Maserati M., Cortelli P., Liguori R., Capellari S., et al. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study. J. Alzheimers Dis. 2018;66:551&#x2013;563. doi: 10.3233/JAD-180409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180409</ArticleId><ArticleId IdType="pubmed">30320576</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson R.W., Slattery C.F., Poole T., Nicholas J.M., Magdalinou N.K., Toombs J., Chapman M.D., Lunn M.P., Heslegrave A.J., Foiani M.S., et al. Cerebrospinal fluid in the differential diagnosis of Alzheimer&#x2019;s disease: Clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimers Res. Ther. 2018;10:32. doi: 10.1186/s13195-018-0361-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0361-3</ArticleId><ArticleId IdType="pmc">PMC5861624</ArticleId><ArticleId IdType="pubmed">29558979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L.Q., Li X.Y., Zhang Y.B., Cheng H.R., Ma Y., Chen D.F., Tao Q.Q., Li H.L., Wu Z.Y. The discriminative capacity of CSF beta-amyloid 42 and Tau in neurodegenerative diseases in the Chinese population. J. Neurol. Sci. 2020;412:116756. doi: 10.1016/j.jns.2020.116756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.116756</ArticleId><ArticleId IdType="pubmed">32142967</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjogren M., Davidsson P., Wallin A., Granerus A.K., Grundstrom E., Askmark H., Vanmechelen E., Blennow K. Decreased CSF-beta-amyloid 42 in Alzheimer&#x2019;s disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement. Geriatr. Cogn. Disord. 2002;13:112&#x2013;118. doi: 10.1159/000048642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000048642</ArticleId><ArticleId IdType="pubmed">11844893</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanga S., Brambilla L., Tasiaux B., Dang A.H., Ivanoiu A., Octave J.N., Rossi D., van Pesch V., Kienlen-Campard P. A Role for GDNF and Soluble APP as Biomarkers of Amyotrophic Lateral Sclerosis Pathophysiology. Front. Neurol. 2018;9:384. doi: 10.3389/fneur.2018.00384.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00384</ArticleId><ArticleId IdType="pmc">PMC5988896</ArticleId><ArticleId IdType="pubmed">29899726</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman A.M., Khandelwal P.J., Stanczyk B.B., Rebeck G.W., Moussa C.E. beta-amyloid triggers ALS-associated TDP-43 pathology in AD models. Brain Res. 2011;1386:191&#x2013;199. doi: 10.1016/j.brainres.2011.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.02.052</ArticleId><ArticleId IdType="pmc">PMC3073036</ArticleId><ArticleId IdType="pubmed">21376022</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusina R., Ridzon P., Kulist&#x2019;ak P., Keller O., Bartos A., Buncova M., Fialova L., Koukolik F., Matej R. Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study. Eur. J. Neurol. 2010;17:23&#x2013;30. doi: 10.1111/j.1468-1331.2009.02717.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02717.x</ArticleId><ArticleId IdType="pubmed">19572947</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijnenburg Y.A., Verwey N.A., van der Flier W.M., Scheltens P., Teunissen C.E. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement. (Amst.) 2015;1:505&#x2013;512. doi: 10.1016/j.dadm.2015.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2015.11.001</ArticleId><ArticleId IdType="pmc">PMC4879490</ArticleId><ArticleId IdType="pubmed">27239528</ArticleId></ArticleIdList></Reference><Reference><Citation>Serio A., Bilican B., Barmada S.J., Ando D.M., Zhao C., Siller R., Burr K., Haghi G., Story D., Nishimura A.L., et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc. Natl. Acad. Sci. USA. 2013;110:4697&#x2013;4702. doi: 10.1073/pnas.1300398110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1300398110</ArticleId><ArticleId IdType="pmc">PMC3607024</ArticleId><ArticleId IdType="pubmed">23401527</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., De Deyn P.P., Bancher C., Cras P., Wiltfang J., Mehta P.D., et al. Improved discrimination of AD patients using beta-amyloid(1&#x2013;42) and tau levels in CSF. Neurology. 1999;52:1555&#x2013;1562. doi: 10.1212/WNL.52.8.1555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.52.8.1555</ArticleId><ArticleId IdType="pubmed">10331678</ArticleId></ArticleIdList></Reference><Reference><Citation>De Riva V., Galloni E., Marcon M., Di Dionisio L., Deluca C., Meligrana L., Bolner A., Perini F. Analysis of combined CSF biomarkers in AD diagnosis. Clin. Lab. 2014;60:629&#x2013;634. doi: 10.7754/clin.lab.2013.130440.</Citation><ArticleIdList><ArticleId IdType="doi">10.7754/clin.lab.2013.130440</ArticleId><ArticleId IdType="pubmed">24779297</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourbouli M., Rentzos M., Bougea A., Zouvelou V., Constantinides V.C., Zaganas I., Evdokimidis I., Kapaki E., Paraskevas G.P. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. Dement. Geriatr. Cogn. Disord. 2017;44:144&#x2013;152. doi: 10.1159/000478979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000478979</ArticleId><ArticleId IdType="pubmed">28848086</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>